A new analysis from the JUPITER study showed that CRESTOR((R)) (rosuvastatin calcium) 20mg reduced the composite primary end point of major cardiovascular (CV) events (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39% (p
Recent Posts
- Better Understanding Of Body's Response To Fasting May Lead To Therapies For Metabolic Disorders
- Fraud Discovery Institute Retracts Herbalife Accusations - California
- Dangers Of Doctors' Shorthand And Bad Writing - Diabetes UK
- Proposed Changes To Civil Claims Funding Will Be Fairer For All Says MDU
- Actelion Pharmaceuticals Announces FDA Approval Of Brand Name For Commercially Available VELETRI® (epoprostenol For Injection)
- Mayo Clinic First In U.S. To Use Newly-Approved FDA Technology To Treat Atrial Fibrillation
- New Jersey Health Department Orders Closure Of Abortion Clinic, Lawsuit Filed
- UCLA's Heart Transplant Program Ranked Best In The U.S.
- FDA Classifies Voluntary Notification Related To SC Catheters And IsoMed Pump Incompatibility As Class I Recall
- VELCADE Induction Followed By VELCADE Maintenance Improves Clinical Outcomes In Previously Untreated Multiple Myeloma Patients
- New Insurance Plans: Good News For People Diagnosed With Cancer